{
    "4 25 2025": {
        "importantArticles": [
            {
                "headline": "Over the last 7 days, the United States market has risen by 4.1%, and over the past 12 months, it is up by 7.9%, with earnings forecasted to grow by 14% annually. In this environment of robust growth, identifying high-growth tech stocks that align with these positive trends can be key to capitalizing on potential opportunities in the market.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9186",
                "source": "Simply Wall St.",
                "ticker": "GILD",
                "title": "3 High Growth Tech Stocks Leading The US Market",
                "url": "https://finance.yahoo.com/news/3-high-growth-tech-stocks-113805195.html"
            },
            {
                "headline": "Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either.  For the period, Gilead's revenue clocked in at $6.67 billion, essentially flat over the same quarter of 2024.  This was offset by improvements in liver disease and human immunodeficiency virus (HIV) medications.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2208",
                "source": "Motley Fool",
                "ticker": "GILD",
                "title": "Why Gilead Sciences Stock Slipped Today",
                "url": "https://finance.yahoo.com/news/why-gilead-sciences-stock-slipped-204336588.html"
            },
            {
                "headline": "Executives told Barron\u2019s that the company is well-positioned to handle potential pharmaceutical tariffs.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Barrons.com",
                "ticker": "GILD",
                "title": "Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.",
                "url": "https://finance.yahoo.com/m/21dbcc7a-0d2c-3a7d-9a28-98c64e3905c9/gilead-sciences-earnings-were.html"
            },
            {
                "headline": "The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for Trodelvy and its cancer cell therapies.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.802",
                "source": "BioPharma Dive",
                "ticker": "GILD",
                "title": "Gilead leans on HIV drugs as oncology sales slow",
                "url": "https://finance.yahoo.com/news/gilead-leans-hiv-drugs-oncology-121000285.html"
            },
            {
                "headline": "Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.765",
                "source": "Investopedia",
                "ticker": "GILD",
                "title": "Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue",
                "url": "https://finance.yahoo.com/news/gilead-sciences-stock-falls-slumping-143010916.html"
            },
            {
                "headline": "Gilead Sciences (GILD) posted an unexpected drop in Q1 revenue amid a surprising miss from cancer dr",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7184",
                "source": "MT Newswires",
                "ticker": "GILD",
                "title": "Gilead Delivers Lackluster Q1 Revenue on Trodelvy Miss, Oppenheimer Says",
                "url": "https://finance.yahoo.com/news/gilead-delivers-lackluster-q1-revenue-152820800.html"
            }
        ],
        "avgScore": -0.18475555555555556,
        "pctChange": 0.004772086699583229
    },
    "4 24 2025": {
        "importantArticles": [
            {
                "headline": "(Reuters) -Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales.  Adjusted earnings per share came in at $1.81, just ahead of the average analysts' estimate of $1.79, as compiled by LSEG.  Gilead's in-line product sales, slight EPS beat and lower expenses were \"positive,\" while the key catalyst for the company's shares will be a \"clean and smooth approval\" in the United States of lenacapavir for preventing HIV, said Jefferies analyst Michael Yee.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "Reuters",
                "ticker": "GILD",
                "title": "Gilead posts profit, says HIV prevention drug on track for mid-June",
                "url": "https://finance.yahoo.com/news/gilead-reports-quarterly-profit-revenue-200902045.html"
            },
            {
                "headline": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street\u2019s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company\u2019s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts\u2019 estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts\u2019 consensus estimates.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "StockStory",
                "ticker": "GILD",
                "title": "Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates",
                "url": "https://finance.yahoo.com/news/gilead-sciences-nasdaq-gild-misses-203349269.html"
            },
            {
                "headline": "Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, came to $1.81 per share. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.82 per share.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.296",
                "source": "Associated Press Finance",
                "ticker": "GILD",
                "title": "Gilead: Q1 Earnings Snapshot",
                "url": "https://finance.yahoo.com/news/gilead-q1-earnings-snapshot-201324122.html"
            },
            {
                "headline": "FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "GILD",
                "title": "Gilead Sciences Announces First Quarter 2025 Financial Results",
                "url": "https://finance.yahoo.com/news/gilead-sciences-announces-first-quarter-200200808.html"
            },
            {
                "headline": "Gilead Sciences (GILD) reported first quarter earnings that topped analyst estimates, but its revenue in the quarter fell short. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above.&nbsp; To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance Video",
                "ticker": "GILD",
                "title": "Gilead Sciences posts mixed Q1 results",
                "url": "https://finance.yahoo.com/video/gilead-sciences-posts-mixed-q1-212213938.html"
            },
            {
                "headline": "Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-211508113.html"
            }
        ],
        "avgScore": 0.25965714285714286,
        "pctChange": -0.02807351214410564
    },
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-132500143.html"
            },
            {
                "headline": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here\u2019s what you need to know.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-report-earnings-120444730.html"
            },
            {
                "headline": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here\u2019s what you need to know.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-report-earnings-120444730.html"
            },
            {
                "headline": "Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-132500143.html"
            }
        ],
        "avgScore": 0.10115,
        "pctChange": -0.0021620204312580277
    },
    "4 22 2025": {
        "importantArticles": [
            {
                "headline": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "Investing.com",
                "ticker": "GILD",
                "title": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
                "url": "https://finance.yahoo.com/news/cantor-initiates-coverage-u-large-134801368.html"
            },
            {
                "headline": "In the trial, the primary endpoint was met, demonstrating a PFS improvement against standard treatment.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4588",
                "source": "Clinical Trials Arena",
                "ticker": "GILD",
                "title": "Gilead reports topline data from Phase III trial of Trodelvy combo therapy",
                "url": "https://finance.yahoo.com/news/gilead-reports-topline-data-phase-142823772.html"
            },
            {
                "headline": "We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an [\u2026]",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.296",
                "source": "Insider Monkey",
                "ticker": "GILD",
                "title": "Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-cheap-nasdaq-135222209.html"
            },
            {
                "headline": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
                "url": "https://finance.yahoo.com/news/5-large-drug-maker-stocks-130600789.html"
            },
            {
                "headline": "We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an [\u2026]",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.296",
                "source": "Insider Monkey",
                "ticker": "GILD",
                "title": "Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-cheap-nasdaq-135222209.html"
            },
            {
                "headline": "In the trial, the primary endpoint was met, demonstrating a PFS improvement against standard treatment.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4588",
                "source": "Clinical Trials Arena",
                "ticker": "GILD",
                "title": "Gilead reports topline data from Phase III trial of Trodelvy combo therapy",
                "url": "https://finance.yahoo.com/news/gilead-reports-topline-data-phase-142823772.html"
            }
        ],
        "avgScore": 0.3683,
        "pctChange": 0.008245617472969015
    },
    "4 21 2025": {
        "importantArticles": [
            {
                "headline": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7906",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
                "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-130008567.html"
            },
            {
                "headline": "Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and...",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7579",
                "source": "Simply Wall St.",
                "ticker": "GILD",
                "title": "Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC",
                "url": "https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-reveals-171455314.html"
            },
            {
                "headline": "FOSTER CITY, Calif., April 21, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy\u00ae (sacituzumab govitecan-hziy) plus Keytruda\u00ae (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS \u2265 10). The st",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "Business Wire",
                "ticker": "GILD",
                "title": "Trodelvy\u00ae Plus Keytruda\u00ae Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer",
                "url": "https://finance.yahoo.com/news/trodelvy-plus-keytruda-demonstrates-statistically-123000256.html"
            },
            {
                "headline": "FOSTER CITY, Calif., April 21, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy\u00ae (sacituzumab govitecan-hziy) plus Keytruda\u00ae (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS \u2265 10). The st",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "Business Wire",
                "ticker": "GILD",
                "title": "Trodelvy\u00ae Plus Keytruda\u00ae Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer",
                "url": "https://finance.yahoo.com/news/trodelvy-plus-keytruda-demonstrates-statistically-123000256.html"
            },
            {
                "headline": "Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and...",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7579",
                "source": "Simply Wall St.",
                "ticker": "GILD",
                "title": "Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC",
                "url": "https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-reveals-171455314.html"
            },
            {
                "headline": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7906",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
                "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-130008567.html"
            }
        ],
        "avgScore": 0.6863666666666667,
        "pctChange": 0.011310268230289099
    },
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8442",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?",
                "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-170600539.html"
            },
            {
                "headline": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-reports-next-140110229.html"
            },
            {
                "headline": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-reports-next-140110229.html"
            },
            {
                "headline": "Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8442",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?",
                "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-170600539.html"
            }
        ],
        "avgScore": 0.53525,
        "pctChange": -0.002008791683887053
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8074",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?",
                "url": "https://finance.yahoo.com/news/gilead-vs-bristol-myers-biotech-170500713.html"
            },
            {
                "headline": "In the latest trading session, Gilead Sciences (GILD) closed at $104.90, marking a -0.74% move from the previous day.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-220015275.html"
            },
            {
                "headline": "We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Gilead Sciences Inc. (NASDAQ:GILD) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined \u2018The Exchange\u2019 on [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "GILD",
                "title": "Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?",
                "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-135422051.html"
            },
            {
                "headline": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
                "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-attracting-130010364.html"
            },
            {
                "headline": "We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Gilead Sciences Inc. (NASDAQ:GILD) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined \u2018The Exchange\u2019 on [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "GILD",
                "title": "Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?",
                "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-135422051.html"
            },
            {
                "headline": "In the latest trading session, Gilead Sciences (GILD) closed at $104.90, marking a -0.74% move from the previous day.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-220015275.html"
            }
        ],
        "avgScore": 0.161325,
        "pctChange": -0.0032417653203127323
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "NORTHAMPTON, MA / ACCESS Newswire / April 15, 2025 / As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered ...",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.765",
                "source": "ACCESS Newswire",
                "ticker": "GILD",
                "title": "Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program",
                "url": "https://finance.yahoo.com/news/gilead-sciences-advancing-oncology-care-125000275.html"
            },
            {
                "headline": "In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500\u2019s 6.9% drop. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "StockStory",
                "ticker": "GILD",
                "title": "3 Reasons GILD is Risky and 1 Stock to Buy Instead",
                "url": "https://finance.yahoo.com/news/3-reasons-gild-risky-1-090543518.html"
            },
            {
                "headline": "In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500\u2019s 6.9% drop. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "StockStory",
                "ticker": "GILD",
                "title": "3 Reasons GILD is Risky and 1 Stock to Buy Instead",
                "url": "https://finance.yahoo.com/news/3-reasons-gild-risky-1-090543518.html"
            },
            {
                "headline": "NORTHAMPTON, MA / ACCESS Newswire / April 15, 2025 / As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered ...",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.765",
                "source": "ACCESS Newswire",
                "ticker": "GILD",
                "title": "Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program",
                "url": "https://finance.yahoo.com/news/gilead-sciences-advancing-oncology-care-125000275.html"
            }
        ],
        "avgScore": 0.69495,
        "pctChange": -0.007570051565552764
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "Political pressure and persistently high interest rates have some wondering if the industry\u2019s model is broken.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "The Wall Street Journal",
                "ticker": "GILD",
                "title": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
                "url": "https://finance.yahoo.com/m/25da5773-f641-3465-b822-ea6b73672626/how-to-play-the-biotech.html"
            },
            {
                "headline": "Political pressure and persistently high interest rates have some wondering if the industry\u2019s model is broken.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "The Wall Street Journal",
                "ticker": "GILD",
                "title": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
                "url": "https://finance.yahoo.com/m/25da5773-f641-3465-b822-ea6b73672626/how-to-play-the-biotech.html"
            }
        ],
        "avgScore": -0.3182,
        "pctChange": 0.027694710244599293
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "NORTHAMPTON, MA / ACCESS Newswire / April 10, 2025 / At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries. In a new ...",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "ACCESS Newswire",
                "ticker": "GILD",
                "title": "PatientView Ranks Gilead \"Best\" at ESG",
                "url": "https://finance.yahoo.com/news/patientview-ranks-gilead-best-esg-125000748.html"
            },
            {
                "headline": "FOSTER CITY, Calif., April 10, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead\u2019s management will host a webcast to discuss the company\u2019s first quarter 2025 financial results and provide a business update.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "GILD",
                "title": "Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025",
                "url": "https://finance.yahoo.com/news/gilead-sciences-release-first-quarter-200500018.html"
            },
            {
                "headline": "FOSTER CITY, Calif., April 10, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead\u2019s management will host a webcast to discuss the company\u2019s first quarter 2025 financial results and provide a business update.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "GILD",
                "title": "Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025",
                "url": "https://finance.yahoo.com/news/gilead-sciences-release-first-quarter-200500018.html"
            },
            {
                "headline": "NORTHAMPTON, MA / ACCESS Newswire / April 10, 2025 / At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries. In a new ...",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "ACCESS Newswire",
                "ticker": "GILD",
                "title": "PatientView Ranks Gilead \"Best\" at ESG",
                "url": "https://finance.yahoo.com/news/patientview-ranks-gilead-best-esg-125000748.html"
            }
        ],
        "avgScore": 0.32985,
        "pctChange": 0.02199206798798649
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.  With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue performing long after: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie went public in 2013, splitting from its former parent company, Abbott Laboratories.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8591",
                "source": "Motley Fool",
                "ticker": "GILD",
                "title": "2 Top Dividend Stocks That Could Set You Up for Life",
                "url": "https://finance.yahoo.com/news/2-top-dividend-stocks-could-110000186.html"
            },
            {
                "headline": "ClearBridge Investments, an investment management company, released its \u201cClearBridge Value Strategy\u201d first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its Russell 1000 Value benchmark, driven by detractors in the energy and financials, which overcame contributions from overweight to energy and underweight to [\u2026]",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "Insider Monkey",
                "ticker": "GILD",
                "title": "Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1",
                "url": "https://finance.yahoo.com/news/multiple-tailwinds-lifted-gilead-sciences-125016979.html"
            },
            {
                "headline": "Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?",
                "url": "https://finance.yahoo.com/news/gilead-gild-beat-estimates-again-161011420.html"
            },
            {
                "headline": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-increases-yet-215005997.html"
            },
            {
                "headline": "Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?",
                "url": "https://finance.yahoo.com/news/gilead-gild-beat-estimates-again-161011420.html"
            },
            {
                "headline": "ClearBridge Investments, an investment management company, released its \u201cClearBridge Value Strategy\u201d first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its Russell 1000 Value benchmark, driven by detractors in the energy and financials, which overcame contributions from overweight to energy and underweight to [\u2026]",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "Insider Monkey",
                "ticker": "GILD",
                "title": "Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1",
                "url": "https://finance.yahoo.com/news/multiple-tailwinds-lifted-gilead-sciences-125016979.html"
            }
        ],
        "avgScore": 0.547325,
        "pctChange": -0.036579557948894004
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "NORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with hepatitis B (HBV) and with advanced HIV. \"Since both viruses ...",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "ACCESS Newswire",
                "ticker": "GILD",
                "title": "Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections",
                "url": "https://finance.yahoo.com/news/gilead-sciences-global-health-challenge-134000249.html"
            },
            {
                "headline": "NORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with hepatitis B (HBV) and with advanced HIV. \"Since both viruses ...",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "ACCESS Newswire",
                "ticker": "GILD",
                "title": "Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections",
                "url": "https://finance.yahoo.com/news/gilead-sciences-global-health-challenge-134000249.html"
            }
        ],
        "avgScore": -0.34,
        "pctChange": 0.01996315059458852
    },
    "4 7 2025": {
        "importantArticles": [
            {
                "headline": "According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.743",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?",
                "url": "https://finance.yahoo.com/news/gilead-gild-buy-wall-street-133010670.html"
            },
            {
                "headline": "According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.743",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?",
                "url": "https://finance.yahoo.com/news/gilead-gild-buy-wall-street-133010670.html"
            }
        ],
        "avgScore": 0.743,
        "pctChange": -0.022081067814488577
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues",
                "url": "https://finance.yahoo.com/news/4-low-beta-healthcare-stocks-122700398.html"
            },
            {
                "headline": "Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues",
                "url": "https://finance.yahoo.com/news/4-low-beta-healthcare-stocks-122700398.html"
            }
        ],
        "avgScore": 0.6597,
        "pctChange": -0.01613056743061626
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-ascends-while-215009856.html"
            },
            {
                "headline": "Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-ascends-while-215009856.html"
            }
        ],
        "avgScore": 0.0,
        "pctChange": -0.04573360101042808
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term",
                "url": "https://finance.yahoo.com/news/why-gilead-sciences-gild-top-134008518.html"
            },
            {
                "headline": "In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-ascends-remains-220016973.html"
            },
            {
                "headline": "In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note",
                "url": "https://finance.yahoo.com/news/gilead-sciences-gild-ascends-remains-220016973.html"
            },
            {
                "headline": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term",
                "url": "https://finance.yahoo.com/news/why-gilead-sciences-gild-top-134008518.html"
            }
        ],
        "avgScore": 0.26335,
        "pctChange": 0.00446867461549256
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "GILD vs. AMGN: Which Stock Is the Better Value Option?",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6486",
                "source": "Zacks",
                "ticker": "GILD",
                "title": "GILD or AMGN: Which Is the Better Value Stock Right Now?",
                "url": "https://finance.yahoo.com/news/gild-amgn-better-value-stock-154007035.html"
            },
            {
                "headline": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration\u2019s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is \u201cnot good for the biotech industry even beyond vaccines.\u201d Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a \u201csignificant negative\u201d for the biopharma and biotech sectors. \u201cNOT GOOD\u201d FOR BIOTECH SECTOR: RBC Capit",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1779",
                "source": "TipRanks",
                "ticker": "GILD",
                "title": "Biotech stocks slide as Marks resignation seen being negative for sector",
                "url": "https://finance.yahoo.com/news/biotech-stocks-slide-marks-resignation-155037694.html"
            },
            {
                "headline": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime&nbsp;here.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1027",
                "source": "Yahoo Finance Video",
                "ticker": "GILD",
                "title": "These biotech names aren't facing 'huge concern' from tariffs",
                "url": "https://finance.yahoo.com/video/biotech-names-arent-facing-huge-113025462.html"
            },
            {
                "headline": "NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years ...",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4067",
                "source": "ACCESS Newswire",
                "ticker": "GILD",
                "title": "Discovering a Breakthrough: Gilead\u2019s Long-Standing Commitment to Helping Change the Course of HIV",
                "url": "https://finance.yahoo.com/news/discovering-breakthrough-gilead-long-standing-125500596.html"
            },
            {
                "headline": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime&nbsp;here.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1027",
                "source": "Yahoo Finance Video",
                "ticker": "GILD",
                "title": "These biotech names aren't facing 'huge concern' from tariffs",
                "url": "https://finance.yahoo.com/video/biotech-names-arent-facing-huge-113025462.html"
            },
            {
                "headline": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration\u2019s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is \u201cnot good for the biotech industry even beyond vaccines.\u201d Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a \u201csignificant negative\u201d for the biopharma and biotech sectors. \u201cNOT GOOD\u201d FOR BIOTECH SECTOR: RBC Capit",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1779",
                "source": "TipRanks",
                "ticker": "GILD",
                "title": "Biotech stocks slide as Marks resignation seen being negative for sector",
                "url": "https://finance.yahoo.com/news/biotech-stocks-slide-marks-resignation-155037694.html"
            }
        ],
        "avgScore": 0.130625,
        "pctChange": 0.005481673409804622
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Yahoo Finance",
                "ticker": "GILD",
                "title": "Moderna, biotech stocks slide following resignation of FDA official Peter Marks",
                "url": "https://finance.yahoo.com/news/moderna-biotech-stocks-slide-following-resignation-of-fda-official-peter-marks-135722653.html"
            },
            {
                "headline": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry\u2019s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500\u2019s 4% decline.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "StockStory",
                "ticker": "GILD",
                "title": "1 Healthcare Stock to Target This Week and 2 to Turn Down",
                "url": "https://finance.yahoo.com/news/1-healthcare-stock-target-week-130153753.html"
            },
            {
                "headline": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry\u2019s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500\u2019s 4% decline.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "StockStory",
                "ticker": "GILD",
                "title": "1 Healthcare Stock to Target This Week and 2 to Turn Down",
                "url": "https://finance.yahoo.com/news/1-healthcare-stock-target-week-130153753.html"
            },
            {
                "headline": "The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Yahoo Finance",
                "ticker": "GILD",
                "title": "Moderna, biotech stocks slide following resignation of FDA official Peter Marks",
                "url": "https://finance.yahoo.com/news/moderna-biotech-stocks-slide-following-resignation-of-fda-official-peter-marks-135722653.html"
            }
        ],
        "avgScore": -0.41695000000000004,
        "pctChange": -0.006871970115924579
    },
    "3 28 2025": {
        "importantArticles": [
            {
                "headline": "Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive human rights policy. The company advised voting against these proposals, slated for discussion at the upcoming annual meeting. Despite broader market challenges like the Dow's 1.7% decline and inflation concerns, Gilead's stock rose 18% over the last quarter, potentially buoyed by its robust Q4...",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6886",
                "source": "Simply Wall St.",
                "ticker": "GILD",
                "title": "Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%",
                "url": "https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-faces-172350086.html"
            },
            {
                "headline": "Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive human rights policy. The company advised voting against these proposals, slated for discussion at the upcoming annual meeting. Despite broader market challenges like the Dow's 1.7% decline and inflation concerns, Gilead's stock rose 18% over the last quarter, potentially buoyed by its robust Q4...",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6886",
                "source": "Simply Wall St.",
                "ticker": "GILD",
                "title": "Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%",
                "url": "https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-faces-172350086.html"
            }
        ],
        "avgScore": 0.6886,
        "pctChange": 0.002325808516872059
    },
    "3 27 2025": {
        "importantArticles": [
            {
                "headline": "The United States market has remained flat over the past week but has shown an 8.5% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in capturing emerging opportunities within this dynamic sector.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9716",
                "source": "Simply Wall St.",
                "ticker": "GILD",
                "title": "High Growth Tech Stocks in the US Market",
                "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-us-110801278.html"
            },
            {
                "headline": "The United States market has remained flat over the past week but has shown an 8.5% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in capturing emerging opportunities within this dynamic sector.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9716",
                "source": "Simply Wall St.",
                "ticker": "GILD",
                "title": "High Growth Tech Stocks in the US Market",
                "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-us-110801278.html"
            }
        ],
        "avgScore": 0.9716,
        "pctChange": 0.005667481402150342
    },
    "coef": -0.15789473684210525,
    "avgCoef": -0.01977599975941221,
    "similar": {
        "HLN": 0.10676691729323308,
        "NGD": 0.09774436090225563,
        "BMY": 0.09022556390977443,
        "KO": 0.02857142857142857
    }
}